The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

In January, the US Food and Drug Administration (FDA) approved the first new type of painkiller ... which is called suzetrigine and sold under the brand name Journavx, is not an opioid.

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...

Vertex also won FDA approval in January for Journavx, a non-opioid targeting acute pain. I'm especially optimistic about the commercial prospects for Journavx. It's the first new class of pain ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U ...